Role of Ly6K in TGF-beta and immune escape pathways of triple negative breast cancer

This study elucidates a novel and clinically relevant role for lymphocyte antigen 6K (LY6K) in cancer cell cycle regulation and survival, and demonstrates how a small molecule, NSC243928, disrupts LY6K function to inhibit cancer cell growth. LY6K is a small GPI-anchored protein normally expressed in testes but aberrantly overexpressed in multiple solid tumors, including breast cancers. Increased LY6K expression correlates with poor survival across many tumor types. The work describes LY6K as required for ERK-AKT and TGF-β pathway activity in cancer cells and essential for in vivo tumor growth. Extending these signaling roles, the authors identify a previously unrecognized function for LY6K in mitosis and cytokinesis mediated via aurora B kinase and its substrate histone H3.

LY6K signaling promotes advancement of the cell cycle and cancer cell proliferation through aurora B–dependent processes. Structural and biochemical interrogation revealed the molecular basis of LY6K interaction with the small molecule NSC243928. The LY6K–NSC243928 interaction was characterized structurally, showing specific contact points in the LY6K protein that mediate binding, and experimentally shown to disrupt LY6K–aurora B signaling. Disruption of LY6K function by NSC243928 impaired cell cycle progression, leading to failed cytokinesis, multinucleation, accumulation of DNA damage, cellular senescence, and apoptosis in cancer cells. Importantly, LY6K is not required for vital organ function, supporting the therapeutic potential of selectively targeting LY6K in cancers that lack effective targeted therapies, such as triple-negative breast cancer (TNBC).

The study integrates structural biology, signaling pathway analysis, and cellular phenotyping to present a compelling rationale for LY6K inhibition as a cancer treatment strategy. The data indicate that blocking LY6K can dismantle critical proliferative and survival pathways in tumor cells, simultaneously inducing mitotic catastrophe and programmed cell death. Given the challenges of treating TNBC and other aggressive malignancies, a LY6K-directed approach could offer a tumor-selective intervention with a favorable safety margin, since LY6K expression is limited in normal tissues. The identification of NSC243928 as a LY6K-binding molecule and demonstration of its functional consequences provide a starting point for development of LY6K-targeted therapeutics. The findings also suggest further avenues for research: detailed preclinical evaluation of LY6K inhibitors in TNBC models, assessment of combination strategies with existing chemotherapies or targeted agents, and exploration of biomarkers to identify patients whose tumors are driven by LY6K-dependent signaling.

Overall, this work positions LY6K as a multifunctional oncogenic regulator operating through ERK-AKT, TGF-β, and aurora B kinase axes, and validates disruption of LY6K–aurora B signaling by NSC243928 as a promising mechanism to impair tumor cell division and survival.